THE MOST DISABLING FORM OF MIGRAINE DISEASE, CHRONIC MIGRAINE, IS COSTLY TO EMPLOYERS ACROSS THE NATION

Photography By © Michael John Coleman 2013

“Lost Productive Time (LPT) Is More Costly & Increases More Rapidly For Those With Chronic Migraine (CM) Than For Those With Episodic Migraine (EM) As Age Increases.”

WASHINGTON, DC / MARCH 29^th , 2013 / MAGNUM – In Chapel Hill, North Carolina MAGNUM just learned that International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has released some interesting data on Chronic Migraine we believe those Migraineurs disabled by Migraine disease, say half the month or more should read this paper published in the empirical journal Value in Health.

According to a press release by ISPOR Chronic Migraine, a condition characterized by 15+ headache days per month, is costly for employers and costs increase rapidly with age according to a new study. Compared to the more common, but less disabling, episodic Migraine, this most severe form of Migraine has been relatively neglected despite the fact that it afflicts more than 3 million Americans.

The study analyzed data from more than 6000 people with Migraine within the American Migraine Prevalence and Prevention Study (AMPP), including 374 participants with chronic Migraine. At age 25, lost productive time for people with chronic Migraine averaged 5.5 hours per week. Study lead author, Daniel Serrano, Ph.D. noted that “By age 64, lost productive time nearly triples reaching almost 14 hours per week. We are astonished to find that older adults with chronic Migraine lose the equivalent of nearly two days per week of productivity”.

These hours of lost productivity are costly for employers. For employed men between the ages of 45 and 54, the annualized cost of lost productivity averaged $4,004 for episodic Migraine and $13,847 for chronic Migraine. Likewise, for women between 45 and 54, costs were higher for CM than EM Migraine ($6,844 vs. $2,347). “Because the employer costs per individual with chronic Migraine are high and because effective treatments are available, employers should consider workplace programs targeting chronic Migraine.” noted study co-author Richard B. Lipton, MD.

The paper, “Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study” is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The American Migraine Prevalence and Prevention Study is funded through a research grant to the National Headache Foundation from Ortho-McNeil Neurologics, Inc., Titusville, NJ. Data analyses and manuscript preparation were provided by Vedanta Research (Chapel Hill, NC) with grant support from Allergan Inc (Irvine, CA) to the National Headache Foundation. To learn more about CM, visit NHF at www.headaches.org.

“By age 64, lost productive time nearly triples reaching almost 14 hours per week. We are astonished to find that older adults with chronic Migraine lose the equivalent of nearly two days per week of productivity”. Study lead author, Daniel Serrano, Ph.D. noted-

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Media Releases Index

Photography By © Michael John Coleman 2013

“Because the employer costs per individual with chronic Migraine are high and because effective treatments are available, employers should consider workplace programs targeting chronic Migraine.” -noted study co-author & Leading Migraine Expert Richard B. Lipton, MD.

Posted by Michael John Coleman, Terri Miller Burchfield on Friday, March 29, 2013 at 09:07 AM | Permalink | Comments (1)

Technorati Tags: AAN, brain, Chronic Migraine, episodic Migraine, lost productivity, MAGNUM, MAGNUM, Migraines, Value in Health, www.migraines.org

Migraine with Aura May Lead to Heart Attack, Blood Clots for Women

AAN 65th Annual Meeting in San Diego Continues.

“After High Blood Pressure, Migraine with Aura was the Second Strongest Single Contributor to Risk of Heart Attacks & Strokes,”

-Says Study author Tobias Kurth, MD, ScD, of INSERM, the French National Institute of Health and Medical Research in Bordeaux and Brigham and Women’s Hospital in Boston

SAN DIEGO, CA, JANUARY 15^th, 2013 /MAGNUM Updated/MARCH 21^st, 2013 -– As the 65^th AAN (The American Academy of Neurology) Annual Meeting, continues to educate the nations practicing 25,000 neurologists and neuroscience professionals now this March 16-23, 2013 in San Diego, California—and more news of interest is coming . MAGNUM will continue to bring you medical news of worth to Migraineurs such as women who have Migraines with aura, which are often visual disturbances such as flashing lights, may be more likely to have problems with their heart and blood vessels, and those on newer contraceptives may be at higher risk for blood clots, according to two studies released today. And as it was noted in the January AAN press release that was presented this week at the American Academy of Neurology’s 65th Annual Meeting in San Diego. And it is now being discussed by Migraine experts face to face over the next few days.

MAGNUM can tell its readers that seeing this interaction first hand is very encouraging to witness as it has in the past. Twenty years ago it was hard to a find a discussion of Migraine disease among medical experts, now they are common place at such events and encouraged between Migraine experts, neurologists, and neuroscience professionals. This can only lead to better care and treatment in the future for Migraineurs. Improving treatments is what these studies are really about in the long run.

The first study showed that Migraine with aura is a strong contributor to the development of major cardiovascular events such as heart attack and stroke. The Women’s Health Study involved 27,860 women, 1,435 of whom had Migraine with aura. During the 15-year study, there were 1,030 cases of heart attack, stroke or death from a cardiovascular cause. The study examined the relative contribution of various vascular risk factors to these major cardiovascular events.

“After high blood pressure, Migraine with aura was the second strongest single contributor to risk of heart attacks and strokes,” said study author Tobias Kurth, MD, ScD, of INSERM, the French National Institute of Health and Medical Research in Bordeaux and Brigham and Women’s Hospital in Boston. Kurth is also a Fellow of the American Academy of Neurology. “It came ahead of diabetes, current smoking, obesity, and family history of early heart disease.”

Kurth cautioned that while people with Migraine with aura have an increased risk, it does not mean that everyone with Migraine with aura will have a heart attack or stroke. He said people with Migraine with aura can reduce their risk in the same ways others can, such as not smoking, keeping blood pressure low and weight down and exercising.

The second study looked at women with Migraine who take hormonal contraceptives and the occurrence of blood clots. The study involved women with Migraine with and without aura who were taking both newer contraceptives such as the contraceptive patch and ring and older contraceptives. Of the 145,304 women who used the contraceptives, 2,691 had Migraine with aura and 3,437 had Migraine without aura.

Women with Migraine with aura were more likely to have experienced blood clot complications such as deep vein thrombosis with all types of contraceptives than women with Migraine without aura. For example, 7.6 percent of women with Migraine with aura who used a newer generation combined hormonal contraceptive had deep vein thrombosis compared to 6.3 percent of women with Migraine without aura, but the timing of the two events is not clear. The occurrence of blood clot complications was also higher in women with Migraine who took contraceptives than women taking the contraceptives who did not have Migraine. “Women who have Migraine with aura should be sure to include this information in their medical history and talk to their doctors about the possible higher risks of newer contraceptives, given their condition,” said study author Shivang Joshi, MD, MPH, RPh, of Brigham and Women’s Faulkner Hospital in Boston and a member of the American Academy of Neurology.

Kurth’s study was supported by the National Institutes of Health. Joshi’s study was supported by the Graham Headache Center Research Fund.

Learn more about Migraine & American Academy of Neurology:

Learn more about Migraine at http://www.aan.com/patients.

American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, Migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy. For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

Posted by Michael John Coleman, Terri Miller Burchfield on Thursday, March 21, 2013 at 10:08 PM | Permalink | Comments (0)

Technorati Tags: AAN, brain, heart attack, MAGNUM, Migraines, stroke

San Diego Plastic Surgeon Discusses Potential Migraine Benefits from Facelifts Procedure

Downtown San Diego

Dr. John Alexander Discusses the Potential Health Benefits That Can Be Gained from a Specialized Facelift Medical Procedure Some Pain Patients May Be Interested In

SAN DIEGO, CA, March 08, 2013 /MAGNUM Updated/March 20, 2013 -- According to a new study of a special facelift technique, debilitating Migraine(s) may become a thing of the past. Dr. John T. Alexander II (www.alexandersurgery.com), a prominent San Diego plastic surgeon with experience treating Migraines with BOTOX, discusses the potential health benefits that patients may gain from this procedure. Issued at the 65^th AAN (The American Academy of Neurology) Annual Meeting, happening now March 16-23, 2013 in San Diego, California . MAGNUM is proud to support our fellow NGO -- AAN, a much larger and older medical group who has embraced with professional passion a strong new aggressive focus on Migraine as a disease around 2000 at which time they where launching teaching modules for Migraine, a neurological illness, not just a headache symptom. This was something needed in American medicine. They are an international professional association of more than 25,000 neurologists and neuroscience professionals dedicated to promoting the highest quality patient-centered neurologic care.

"This facelift technique is a new approach toward Migraine treatment that addresses the pain at the source, rather than treating the symptoms," explains Dr. Alexander. "My practice already offers advanced Migraine treatment using BOTOX to target tightened muscles that can cause migraine pain. But for some people, a surgical solution could lead to better outcomes and long-lasting relief of Migraine symptoms."

The study in question, published in the journal Plastic and Reconstructive Surgery, examines patients with Migraines that have specific origins in a localized area of the head. Preliminary research was undertaken through BOTOX injections directly to the trigger points. A portion of the patients who experienced relief of Migraine symptoms as a result of the temporary muscle paralysis gained from the BOTOX then received the specialized facelift surgery. Fifty-seven percent of the patients who had surgery reported that their Migraines had been completely eliminated, and 84 percent reported at least a 50 percent improvement in symptoms.

"This technique could mean a huge improvement in the overall quality of life for Migraine sufferers," says Dr. Alexander. "At my practice, we've already seen great success with treating migraine treatments using BOTOX injections and the benefits are really rewarding."

Although primarily used for treating skin wrinkles, the mechanism of BOTOX makes it an effective Migraine treatment as well. BOTOX paralyzes the muscles that cause "dynamic wrinkles" due to repeated facial expressions. Similarly, BOTOX injections can paralyze the muscles that may be responsible for triggering a Migraine attack. It's thought that BOTOX may also calm the nerve endings on the surface of the brain that cause irritation and inflammation and lead to severe pain.
BOTOX is FDA-approved to treat those who suffer chronic Migraines. Since the body absorbs BOTOX over the next several months, maintenance treatments are recommended for ongoing relief of symptoms.

"I will be following the studies of this new surgical treatment of Migraines to see if the technique is worth incorporating into our practice in the future," says Dr. Alexander. "Increasing quality of life for our patients is always our top priority."

Alexander Cosmetic Surgery (http://www.alexandersurgery.com) has been San Diego's leader in facial rejuvenation and cosmetic plastic surgery since 1964. Led by father and son duo, Drs. John T. Alexander, M.D., and John T. Alexander II, M.D., F.A.C.S., J.D., the clinic has a history of patient dedication and care, while leading the way with innovative treatments such as the QuickLift procedure.

Oh course local Migraineurs stopped by to visit.

For more on Dr. Alexander:

Contact Information:
John Alexander
Alexander Plastic Surgery
Doctor
9339 Genesee Avenue
San Diego, CA
US 92121
Voice: (888) 463-9532
E-Mail: Email us Here
Website: Visit Our Website

Posted by Michael John Coleman, Terri Miller Burchfield on Friday, March 08, 2013 at 08:49 PM | Permalink | Comments (0)

Technorati Tags: AAN, BOTOX, John Alexander, Migraine, San Diego

First FDA-Approved Migraine Disease Patch!

NuPathe Inc. graphics superimposed.

NuPathe's Zecuity Approved by the FDA for the Acute Treatment of Migraine With New Delivery System for the Patient

CONSHOHOCKEN, PA— SUNDAY, JANUARY 27^th, 2013 — (MAGNUM) — According to Marketwire on January 17^th NuPathe Inc. (NASDAQ: PATH) announced that the U.S. Food and Drug Administration (FDA) had approved Zecuity™ (sumatriptan iontophoretic transdermal system) for the acute treatment of Migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed Migraine abortive medication, through the skin. Zecuity provides relief of both Migraine head pain and migraine-related nausea (MRN).

"The approval of Zecuity represents a major milestone for NuPathe and Migraine sufferers," said Armando Anido, CEO of NuPathe. "As the first and only FDA-approved Migraine patch, we believe Zecuity will be a game-changing treatment option for millions of migraine patients, especially those with Migraine-related nausea. We thank the patients and physicians who participated in our clinical trials as well as our employees for their support throughout the development of Zecuity. We now intensify our focus to securing commercial partners and preparing for the launch of Zecuity expected in the fourth quarter of this year."

"In addition to severe [Migraine] pain, Migraine patients present with other significant symptoms, which commonly includes Migraine-related nausea," said Lawrence C. Newman, MD, FAHS, FAAN, Director of the Headache Institute at St. Luke's-Roosevelt Hospital in New York. "For these patients, physicians need to assess and offer treatments tailored to each individual patient's array of Migraine symptoms. In fact, the American Academy of Neurology guidelines recommend a non-oral route of administration for Migraineurs who experience nausea or vomiting as significant symptoms."

"Migraine-related nausea can be as debilitating as Migraine headache pain itself," said study investigator Stephen D. Silberstein, MD, FACP, FAHS, FAAN, Professor of Neurology and Director of the Jefferson Headache Center in Philadelphia. "Treatments bypassing the GI tract may be the best way to treat these patients." MAGNUM would like to point out that Dr. Silberstein is one of the nation’s finest Migraine researchers.

Zecuity was approved based upon an extensive development program with phase 3 trials that included 800 patients using more than 10,000 Zecuity patches. In these trials, Zecuity was proven safe and effective at treating Migraine and relieving its cardinal symptoms (headache pain, Migraine-related nausea and sensitivity to light and sound) two hours after patch activation.

In the phase 3 pivotal study, twice as many patients treated with Zecuity achieved freedom from headache pain at two hours compared with placebo (18% and 9%, respectively). Additionally, 53% of patients treated with Zecuity achieved relief from headache pain and 84% were nausea free at two hours (29% and 63%, respectively, with placebo). The incidence of triptan-associated adverse events known as "atypical sensations" and "pain and other pressure sensations" was 2% each in Zecuity-treated patients. The most common (greater than 5%) side effects of Zecuity were application site pain, tingling, itching, warmth and discomfort.

What MAGNUM finds most exciting about the FDA’s approval of the Zecuity™ sumatriptan iontophoretic transdermal system is its benefits to who tend to vomit up Migraine medication before it has taken effect. This is a welcome treatment to the Migraineurs toolkit.

About Zecuity
ZECUITY™ (sumatriptan iontophoretic transdermal system) is indicated for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch applied to the upper arm or thigh during a migraine. Following application and with a press of a button, Zecuity initiates transdermal delivery (through the skin), bypassing the gastrointestinal tract. Throughout the four-hour dosing period, the microprocessor within Zecuity continuously monitors skin resistance and adjusts drug delivery accordingly to ensure delivery of 6.5 mg of sumatriptan, the most widely prescribed migraine medication, with minimal patient-to-patient variability.

NuPathe Inc. graphic.

Important Safety Information
Patients should not take ZECUITY if they have heart disease, a history of heart disease or stroke, peripheral vascular disease (narrowing of blood vessels to your legs, arms, stomach or kidney), transient ischemic attack (TIA) or problems with blood circulation, uncontrolled blood pressure, migraines that cause temporary paralysis on one side of the body or basilar migraine, Wolff-Parkinson-White syndrome or other disturbances of heart rhythm. Very rarely, certain people, even some without heart disease, have had serious heart-related problems after taking triptans like ZECUITY.

Patients should not use ZECUITY if they have taken other Migraine medications such as ergotamine medications or other triptans in the last 24 hours or if they have taken monoamine oxidase-A (MAO-A) inhibitors within the last 2 weeks.

Patients should not use ZECUITY during magnetic resonance imaging (MRI).

Patients should not use ZECUITY if they have an allergy to sumatriptan or components of ZECUITY or if they have had allergic contact dermatitis (ACD) following use of ZECUITY. If patients develop ACD, they should talk to their healthcare provider before using sumatriptan in another form.

ZECUITY, like other triptans, may be associated with a potentially life-threatening condition called serotonin syndrome, mainly when used together with certain types of antidepressants including serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).

Patients should tell their healthcare provider before using ZECUITY if they have heart disease or a family history of heart disease, stroke, high cholesterol or diabetes; have gone through menopause; are a smoker; have had epilepsy or seizures or if they are pregnant, nursing or thinking about becoming pregnant.

The most common side effects of ZECUITY are application site pain, tingling, itching, warmth and discomfort. Most patients experience some skin redness after removing ZECUITY. This redness typically goes away in 24 hours.

Please see full Prescribing Information for ZECUITY.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Patients and healthcare providers interested in more information on Zecuity should visit www.zecuity.com.

About Migraine and Migraine-Related Nausea (MRN)
Migraine is a debilitating neurological disease afflicting a large underserved patient population. Migraine is characterized by headache pain accompanied by associated neurological and GI symptoms including nausea, vomiting, photophobia, and phonophobia.^1,2 In the U.S., 31 million adults, with approximately three times as many women as men,³ suffer from migraine.^3,4,5 Of the 16 million migraine patients who are diagnosed and treated, approximately eight million experience migraine-related nausea (MRN) in at least half of their migraine attacks.⁶These frequent-MRN patients report significantly more migraine symptom burden and experience significantly more interference with work, social and family life.⁶ Many migraine patients who experience MRN delay or avoid taking orally administered medications due to nausea or vomiting.⁷

NuPathe Inc. graphic.

About NuPathe
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product, Zecuity (sumatriptan iontophoretic transdermal system), has been approved by the FDA for the acute treatment of migraine with or without aura in adults. Zecuity is expected to be available by prescription in the fourth quarter of 2013. In addition to Zecuity, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for Zecuity and its other product candidates in the U.S. and territories throughout the world.

For more information about NuPathe, please visit our website and our blog at www.nupathe.com. You can also follow us on StockTwits (stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare (slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com).

References

1. ICHD-II. Cephalagia 2004; 24 (Suppl 1).
2. Lipton, R. et al. Classification of primary headaches. Neurology. 2004:63:427-435.
3. Lipton, R. et al. Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. Headache, July/August 2001: p. 646.
4. US Census Data. 1999, accessed at http://www.census.gov/prod/2001pubs/p23-205.pdf 01/03/13; and 2010, accessed at http://www.census.gov/2010census/data/.
5. NuPathe Analysis.
6. Lipton, R. et al. "Frequency and Burden of Headache-Related Nausea: Results from the American Migraine Prevalence and Prevention (AMPP) Study." Headache 2012:53:93-103. Funded by a research grant from NuPathe Inc.
7. Silberstein, S. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995;35:387-396.

Contact Information:

MEDIA CONTACTS:
6 Degrees
Tony Plohoros
(908) 940-0135
tplohoros@6degreespr.com

Sage Strategic Marketing
Jennifer Guinan
(610) 410-8111
jennifer@sagestrat.com

Posted by Michael John Coleman, Terri Miller Burchfield on Sunday, January 27, 2013 at 01:54 PM | Permalink | Comments (0)

Technorati Tags: approval, FDA, MAGNUM, Migraine, Zecuity™

Migraine with Aura May Lead to Heart Attack, Blood Clots for Women

San Diego At Night

“Migraine with Aura was the Second Strongest Single Contributor to Risk of Heart Attacks and Strokes”

SAN DIEGO, CALIFORNIA – TUESDAY, JANUARY 15^th, 2013 — Updated JANUARY 22^nd , (MAGNUM) — According to Newswise —Women who have Migraines with aura, which are often visual disturbances such as flashing lights, may be more likely to have problems with their heart and blood vessels, and those on newer contraceptives may be at higher risk for blood clots, according to two studies released today that will be presented at the American Academy of Neurology’s 65th Annual Meeting in San Diego, March 16 to 23, 2013.

MAGNUM has long supported a position that there is a strong relationship with stroke and Migraine. In addition we have been grateful for the studies supported by American Academy of Neurology’s annual meetings. As we can see this during Spring’s 65^th Meeting will add to our understanding of Migraine disease.

Women with migraine with aura were more likely to have experienced blood clot complications such as deep vein thrombosis with all types of contraceptives than women with Migraine without aura. For example, 7.6 percent of women with migraine with aura who used a newer generation combined hormonal contraceptive had deep vein thrombosis compared to 6.3 percent of women with migraine without aura, but the timing of the two events is not clear. The occurrence of blood clot complications was also higher in women with Migraine who took contraceptives than women taking the contraceptives who did not have Migraine.

“The Occurrence of Blood Clot Complications Was Also Higher in Women With Migraine Who Took Contraceptives…”

“Women who have Migraine with aura should be sure to include this information in their medical history and talk to their doctors about the possible higher risks of newer contraceptives, given their condition,” said study author Shivang Joshi, MD, MPH, RPh, of Brigham and Women’s Falkner Hospital in Boston and a member of the American Academy of Neurology.

Learn more about Migraine at http://www.aan.com/patients.

Kurth’s study was supported by the National Institutes of Health. Joshi’s study was supported by the Graham Headache Center Research Fund.

The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, Migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook,Twitter, Google+ and YouTube.

Posted by Michael John Coleman, Terri Miller Burchfield on Tuesday, January 15, 2013 at 07:47 PM | Permalink | Comments (0)

Technorati Tags: AAN, MAGNUM, Migraine, stroke

Pain Magazine Launches NEW Website of Interest to the Migraine Community

Screen Shot of the well organized new PainPathways.org website, visit it today.

PainPathways Goes Beyond Print to Provide Relevant Information and Inspiration to Sufferers and Caregivers Through Their New, Feature-Filled Website.

WINSTON-SALEM, NORTH CAROLINA, TUESDAY, DECEMBER 18^th, 2012— (MAGNUM) — A Christmas gift for our readers as there are no competitors when it comes to helping aid the suffering, so MAGNUM welcomes this new pain website to aid Migraineurs and other pain patients as we head into 2013. As reported to us by PainPathways publication, an important part of the pain community. We at MAGNUM are happy to bring you the following information about a new website from the same group – As the first and only chronic, acute and cancer pain magazine, PainPathways is an important resource for people with pain, caregivers and physicians.Richard Rauck, MD, an international pain management specialist, created PainPathways in 2007 to connect and inspire people who live with pain, both personally and professionally, offering in-depth information on new treatments, integrative therapies and current research.

Need a last minute Christmas gift for a Migraineur or a pain sufferer in your life? Look what they have just for us!

This December, PainPathways launched a new, more dynamic website (painpathways.org) that provides updated content between publication of each print issue. Exclusive online content includes inspirational quotes, book reviews, healthy recipes and follow-up interviews with celebrities who have been featured in past issues. Readers can also comment on articles, share stories and provide feedback.

A wellness blog written by Linda Ruehlman, PhD, a social and health psychologist, offers guidance on pain management, health and fitness, depression, social support and more.

“The goal of our new website, as well our presence on Facebook and Pinterest, is to engage readers and continue building a community. There is power in sharing stories, ideas, resources and strategies that help manage pain,” says Amy Taylor North, senior managing editor.

Subscriptions for individuals, gift subscriptions and bulk subscriptions for physician offices are easy to order on the new website.

As always, PainPathways’ mission is to inform and inspire readers and encourage wellness.

PainPathways is a quarterly publication produced in print and digital editions for patients, physicians and caregivers who live with or manage acute, chronic and cancer pain. Its headquarters are located in Winston-Salem, North Carolina. To learn more and subscribe, visit painpathways.org, Facebook or Pinterest.

FOR MORE INFORMATION: